Fungal & Yeast Expression

Fungal & Yeast Expression Services

Secretion. Glycosylation. Complex Chemistry at Scale.

At Mika Biologics, we believe fungi and yeast are the quiet powerhouses of biologics manufacturing. While many CDMOs lean heavily on E. coli or mammalian cells, we recognize that yeast and filamentous fungi offer a sweet spot of scalability, secretion efficiency, and post-translational sophistication.

From Pichia pastoris and Saccharomyces cerevisiae to filamentous hosts like Aspergillus and Trichoderma, fungal expression systems unlock possibilities that bacteria cannot achieve and that mammalian systems deliver only at great cost. Glycosylated enzymes, complex metabolites, secreted proteins, and multi-step biosynthetic pathways all find their natural home in fungi and yeast.

Mika Biologics CDMO

At Mika Biologics, we have made fungal and yeast expression a core platform, integrating advanced strain engineering, precision fermentation, and downstream workflows to help innovators realize their most ambitious projects.

Why Fungal & Yeast Systems?

Each expression system comes with strengths and trade-offs. Bacteria are fast but lack post-translational modifications. Mammalian cells are capable but slow and costly. Fungi and yeast strike a unique balance:

  • Pichia pastoris – A versatile yeast, capable of secreting recombinant proteins at grams-per-liter yields, with customizable glycosylation.
  • Saccharomyces cerevisiae – The “workhorse of biotechnology,” ideal for enzymes, VLPs, and GRAS (Generally Recognized as Safe) applications.
  • Aspergillus & Trichoderma – Filamentous fungi that naturally produce and secrete high levels of carbohydrases, proteases, and specialty metabolites.

Key advantages of fungal & yeast systems:

  • Secretion Efficiency – Many proteins secreted directly into the medium, simplifying downstream.
  • Glycosylation Capability – Human-like or engineered glycosylation for therapeutic proteins.
  • Robust Fermentation – Fungi thrive in industrial-scale fermentors with consistent productivity.
  • Complex Pathways – Ideal for producing secondary metabolites, specialty chemicals, and multi-enzyme cascades.

For biologics that demand both complexity and scale, fungal and yeast hosts are unmatched.

Our Fungal & Yeast Services

Mika Biologics offers a comprehensive fungal/yeast portfolio, spanning strain engineering, process development, and GMP manufacturing.

1. Pichia pastoris Expression

Pichia is one of the most widely used expression systems for recombinant proteins. Its ability to secrete proteins at high titers and undergo glycosylation makes it a leading alternative to mammalian cells.

Capabilities:

  • Custom Pichia Strain Development – AOX1 and GAP promoter systems.
  • Glycoengineering – Human-like N-glycans for therapeutic proteins.
  • Secreted Protein Production – Simplified downstream with extracellular proteins.
  • High-Density Fermentation – Achieving yields up to tens of grams per liter.

Applications:

  • Cytokines, enzymes, VLPs, and nanoparticles.
  • Antibody fragments (scFvs, Fabs).
  • Glycosylated industrial enzymes.

Mika specializes in Pichia optimization, ensuring consistency, reproducibility, and bioactivity at scale.

2. Saccharomyces cerevisiae Platforms

Known as baker’s yeast, Saccharomyces is both safe and versatile. Its GRAS status makes it ideal for therapeutic proteins, nutraceuticals, and food biotech.

Capabilities:

  • Plasmid & Genomic Integration – Stable expression systems.
  • VLP Production – Yeast assembly of virus-like particles for vaccines.
  • Metabolite Production – Secondary metabolites and nutraceutical compounds.
  • Industrial Scale-Up – Yeast fermentors scaled from pilot to commercial volumes.

Applications:

  • Recombinant vaccines.
  • Food and alternative protein products.
  • Enzyme production for diagnostics and therapeutics.

Saccharomyces offers a bridge between therapeutic biotech and food innovation, and Mika is positioned to support both.

3. Aspergillus & Filamentous Fungi

Aspergillus and related fungi are masters of secretion and complex chemistry. Unlike yeasts, filamentous fungi produce high levels of enzymes and specialty metabolites naturally.

Capabilities:

  • High-Yield Enzyme Production – Carbohydrases, proteases, lipases.
  • Multi-Step Biosynthetic Pathways – Complex molecules built via fungal consortia.
  • Secondary Metabolites – Natural products and specialty chemicals.
  • Co-Culture Engineering – Fungal consortia optimized for pathway complexity.

Applications:

  • Industrial enzymes.
  • Bioplastics and sustainable chemicals.
  • Specialty metabolites for therapeutics.

At Mika, filamentous fungi are not an afterthought—they are a strategic platform for high-value, complex projects.

Why Choose Mika for Fungal & Yeast Expression?

1. Microbial-First Philosophy

Most CDMOs treat fungi and yeast as niche. Mika treats them as core systems equal to bacteria and cell-free extracts.

2. End-to-End Expertise

From strain development to GMP, we handle the entire fungal/yeast lifecycle.

3. Glycoengineering Capabilities

We offer glycosylation pathway customization for therapeutic-grade proteins.

4. Complex Chemistry Specialists

Multi-step biosynthesis and fungal consortia are our specialty, giving clients access to advanced chemistry platforms.

5. Scalable Infrastructure

In-house fermentation up to 2000 L, with partnerships scaling to 20,000 L.

Technical Infrastructure

Our fungal & yeast services are supported by advanced infrastructure:

  • Fermentation – stainless steel & single-use fermentors (1–2000 L).
  • Secretion Pathways – engineered strains for extracellular yields.
  • Downstream Processing – homogenization, TFF, chromatography, lyophilization.
  • Analytics – HPLC/UHPLC, glycan analysis, mass spectrometry, ELISA.
  • Quality – GMP-ready, ISO-aligned, FDA-registered, EU-compliant.

Client Applications & Case Studies

  • Biopharma Innovator – Pichia platform scaled to GMP for a glycosylated cytokine.
  • Vaccine Developer – Saccharomyces-based VLPs validated in preclinical immunogenicity.
  • Industrial Biotech – Aspergillus fermentation scaled to 10,000 L for carbohydrase production.
  • Alt Protein Startup – Fungal mycoprotein platform developed for novel food proteins.

The Future of Fungal & Yeast at Mika

We see fungi and yeast as the frontier of sustainable biologics:

  • Human-Like Glycoengineering – yeast strains producing therapeutic-grade antibodies.
  • Fungal Consortia for Bioplastics – multi-strain fermentations producing bio-based polymers.
  • Next-Gen Food Proteins – scaling mycoproteins and fermented dairy proteins.
  • Cross-Platform Synergies – fungal enzymes feeding cell-free systems, yeast scaffolds supporting immune biologics.

Mika is building a fungal/yeast ecosystem that integrates biotechnology, sustainability, and therapeutics.

Closing Thoughts

Fungal and yeast expression systems represent a powerful blend of secretion efficiency, glycosylation capability, and industrial scalability. They are the natural choice for glycosylated enzymes, vaccine scaffolds, secondary metabolites, and alternative proteins.

At Mika Biologics, we don’t treat fungi and yeast as an afterthought—we treat them as pillars of our microbial-first platform. By mastering Pichia, Saccharomyces, and Aspergillus, we help clients unlock projects that mammalian systems cannot support and that generic microbial houses overlook.

Email our team your questions are info@mikabiologics.com